Retatrutide beneficial as a monotherapy in adults with T2D inadequately controlled with diet and exercise alone
WEDNESDAY, June 10, 2026 (HealthDay News) — For adults with type 2 diabetes (T2D) that is inadequately controlled with diet and exercise alone, retatrutide, a triple hormone receptor agonist, is associated with significant improvements in glycemic control and body weight reductions, according to a study published online June 6 in The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.
Harpreet S. Bajaj, M.D., from LMC Diabetes and Endocrinology in Brampton, Ontario, Canada, and colleagues examined the efficacy and safety of retatrutide as a monotherapy in a 40-week phase 3 trial involving adults with type 2 diabetes inadequately controlled by diet and exercise alone. Participants were randomly assigned to receive retatrutide (4 mg, 9 mg, or 12 mg) or placebo by once-weekly subcutaneous injection (134, 133, 136, and 134 individuals, respectively).
The researchers found that for the treatment regimen estimand, the mean change from baseline in hemoglobin A1c concentration was −1.69, −1.86, and −1.94 percent with 4, 9, and 12 mg of retatrutide, respectively, versus −0.81 percent with placebo, resulting in estimated treatment differences of −0.88, −1.04, and −1.12 percent, respectively, versus placebo. From baseline, the mean percentage change in body weight was −11.5, −13.9, and −15.3 percent with 4, 9, and 12 mg of retatrutide, respectively, versus −2.6 percent with placebo. The most frequent adverse events were mainly mild-to-moderate gastrointestinal events, which reduced over time.
“The magnitude of weight loss observed with retatrutide has the potential to slow disease progression and reshape how we treat and manage type 2 diabetes,” Bajaj said in a statement.
Several authors disclosed ties to biopharmaceutical companies, including Eli Lilly, which is developing retatrutide and funded the study.
Abstract/Full Text (subscription or payment may be required)
.jpg)
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions 
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria 
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50 
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy 
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis 
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions 
